Use of lipid-lowering drugs from 1990 to 1994: An international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden

European Journal of Clinical Pharmacology

Volumn 53, Issue 3-4, 1997, Pages 185-189

  Magrini, N ^a   Einarson, T ^b,c   Vaccheri, A ^a   McManus, P ^d   Montanaro, N ^a   Bergman, U ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF TORONTO   (Canada)

^d Dept of Health and Family Services ^*  (Australia)

Author keywords

International comparison; Lipid lowering drugs

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; COLESTIPOL; GEMFIBROZIL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; DRUG UTILIZATION; FEMALE; FINLAND; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; NORWAY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; REIMBURSEMENT; RISK FACTOR; SWEDEN;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTILIPEMIC AGENTS; AUSTRALIA; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; FINLAND; HUMANS; INFANT; INFANT, NEWBORN; ITALY; MALE; MIDDLE AGED; NORWAY; SEX FACTORS; SWEDEN; TIME FACTORS;

EID: 0031444773     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050360     Document Type: Article

References (34)

1. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM Jr, Grundy SM, Rakita L, Robertson RM, Weisfeldt ML, Cleeman JJ, Wilson PW, Clarkson TB, Hay JW, Goodman DS (1990) The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 81: 1721-1733
2. Naylor DC, Basinski A, Frank JW, Rachlis MM [on behalf of The Toronto Working Group on Cholesterol Policy] (1990) Asymptomatic hypercholesterolemia: a clinical policy review. J Clin Epidemiol 43: 1021-1122
3. Stamler J (1992) Established major coronary risk factors. In: Marmot M, Elliott P (eds) Coronary heart disease epidemiology from aetiology to public health. Oxford University Press, Oxford, pp 35-66
4. Henwood JM, Heel RC (1988) Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidemia. Drugs 36: 429-454
5. Todd PA, Goa KL (1990) Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 40: 583-607
6. O'Connor P, Feely J, Shepherd J (1990) Lipid lowering drugs. BMJ 300: 667-672
7. Sheldon TA, Davey Smith G (1993) Consensus conferences as drug promotion. BMJ 341: 100-102
8. Law MR, Thompson SG, Wald NJ (1994) Assessing possible hazards of reducing serum cholesterol. BMJ 308: 373-379
9. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A (1994) Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 308: 363-366
10. Law MR, Wald NJ, Thompson SG (1994) By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308: 367-373
11. Davey Smith G, Egger M (1994) Commentary on cholesterol papers-statistical problems. BMJ 308: 1025-1027
12. Law MR, Wald NJ (1994) Commentary on cholesterol papers-disagreements are not substantial. BMJ 308: 1027-1029
13. Muldoon MF, Manuck SB, Matthews KA (1990) Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 301: 309-314
14. Davey Smith G, Song F, Sheldon TA (1993) Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 306: 1367-1373
15. Editorial (1989) The number of patients who use the new antilipemic agents has doubled since their introduction on the market. Läkartidningen 86: 3583-3585
16. Boumendil EF (1994) Descriptive study of lipid-modulating drug use in a French professional population. J Clin Epidemiol 47: 1163-1171
17. Nordic Council on Medicines (1993) Nordic Statistics on Medicines 1990-1992 Nordic Council on Medicines, Uppsala, Sweden
18. McCormack JP, Rangno RE (1994) An evaluation and critique of the use of lipid-lowering drugs in a population base of 400 000 patients over the age of 65. Can J Clin Pharmacol 1: 27-32
19. Commonwealth Department of Human Services and Health (1996) Australian statistics on medicines 1994. Government Publishing Service, Canberra
20. National Agency for Medicines and Social Insurance Institution (1995) Finnish Statistics on Medicines, Helsinki
21. Montanaro N, Vaccheri A, Magrini N, Battilana M (1992) FARMAGUIDA: a databank for the analysis of the Italian drug market and drug utilization in general practice. Eur J Clin Pharmacol 42: 395-399
22. Norsk medisinaldepot AS (1995) Swedish drug Statistics 1990-1994, Oslo
23. Nordenstam I, Wennberg M, Kristoferson K (1995) Svensk läkemedelsstatistik. Apoteksbolaget Stockholm
24. WHO Collaborating Centre for Drug Statistics Methodology (1996) Guidelines for ATC classification and DDD assignment. WHO Collaborating Centre for Drug Statistics Methodology, Oslo
25. Committee of principal Investigators (1984) WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serun cholesterol: final mortality follow-up. Lancet ii: 600-604
26. Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ (1994) Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 343: 1554-1555
27. Corti MC, Guralnik JM, Salive ME, Harris T, Field TS, Wallace RB, Berkman LF, Seeman TE, Glynn RJ, Hennekens CH, Havlik RZ (1995) HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 274: 539-544
28. Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI, Tsukahara R, Ostfeld AM, Berkman LF (1994) Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in person older than 70 years. JAMA 272: 1335-1340
29. Beaglehole R (1991) Coronary heart disease and elderly people. BMJ 303: 69-70
30. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A (1994) Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90: 583-612
31. Wahlström R (1996) Lipid-lowering drugs in Norway and Sweden 1988-1994. Sales and prescribing. In: Beermann B, Madsen S, Strandberg K, Wærstad A, Westbje O (eds) Treatment of hyperlipidaemia. Uppsala: Medical Products Agency, pp 79-91
32. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307
33. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival study (4S). Lancet 344: 1383-1389
34. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. New Engl J Med 335: 1001-1009